Skip to ContentSkip to Navigation
How to find us L.B.M. Hijmering-Kappelle, MSc


Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles

ctDNA a promising predictive marker for treatment with PD-1 inhibitors in KRAS mutated NSCLC after platinum based chemotherapy

PD-L1 expression, CD8 cells and MHC-class-1 Beta-2-microglobulin expression in advanced non-small lung cancer

Molecular Tumor Board treatment predictions on rare EGFR exon 20 mutations

Onderzoek naar biomarkers in plasma voor het (snel) vaststellen van een tumorrespons bij de behandeling met nivolumab bij KRAS-gemuteerd niet-kleincellig longkanker: Een exploratief onderzoek

Opnieuw biopteren bij progressie van longkanker

Treatment decision-making of rare ERBB2 (HER2) mutations in lung cancer; a role for multidisciplinary molecular tumor boards: A role for multidisciplinary molecular tumor boards

Predicting outcome after acute basilar artery occlusion based on admission characteristics

Read more